Johnson & Johnson will acquire a manufacturer of 3D printed titanium implants in an effort to enhance its implant portfolio, the company has announced.
Johnson & Johnson Medical will acquire Emerging Implant Technologies (EIT) to give its orthopaedics business, DePuy Synthes, access to EIT’s portfolio of implants. EIT’s implants utilise advanced cellular titanium, consisting of an open and interconnected porous structure that allows bone to grow into the implant.
The acquisition gives De Puy Synthes access to 3D printed cellular titanium which can be used for both minimally invasive and open spinal surgery.
“Our goal is to offer a complete portfolio of interbody solutions that provides surgeons with even more options for the treatment of their patients,” said Aldo Denti, company group chairman of DePuy Synthes. “We are excited to welcome the skilled team at EIT, and together, we aspire to bring to market technologies that allow surgeons to perform spinal fusion procedures reliably and with consistent outcomes.”
The company states that EIT’s portfolio will complement some of its recent technology introductions, designed to treat patients with degenerative disc disease.